{"gene":"SMYD3","run_date":"2026-06-10T07:46:37","timeline":{"discoveries":[{"year":2004,"finding":"SMYD3 SET domain possesses histone H3-lysine 4 (H3K4)-specific methyltransferase activity, which is enhanced in the presence of heat-shock protein HSP90A. SMYD3 forms a complex with RNA polymerase II through an interaction with the RNA helicase HELZ and binds to the promoter motif 5'-CCCTCC-3' to transactivate downstream oncogenes and cell-cycle genes.","method":"In vitro methyltransferase assay, Co-immunoprecipitation, promoter binding assay, siRNA knockdown with proliferation readout","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro enzymatic assay plus Co-IP plus functional siRNA knockdown, founding paper replicated by multiple subsequent labs","pmids":["15235609"],"is_preprint":false},{"year":2007,"finding":"SMYD3 methylates vascular endothelial growth factor receptor 1 (VEGFR1) at lysine 831, located in the kinase domain; this methylation enhances VEGFR1 kinase activity in cells.","method":"In vitro methyltransferase assay, mass spectrometry identification of methylated residue, cell-based kinase activity assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro assay plus site identification plus cellular kinase readout, single lab","pmids":["18006819"],"is_preprint":false},{"year":2007,"finding":"N-terminal cleavage of SMYD3 (removing 34 amino acids) increases its histone methyltransferase activity. The N-terminal region mediates association with HSP90alpha, and mutations at conserved glycines 15 and 17 also increase HMTase activity, indicating the N-terminus negatively regulates enzymatic activity.","method":"Protein truncation/mutagenesis, in vitro HMTase assay, Co-immunoprecipitation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with in vitro enzymatic assay and Co-IP, single lab","pmids":["17998933"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of full-length human SMYD3 in complex with S-adenosyl-L-homocysteine at 2.8 Å resolution reveals that the C-terminal domain contains a tetratricopeptide repeat (TPR) domain that together with the SET and post-SET domains forms a deep, narrow substrate-binding pocket. The hydroxyl group of Tyr239 is critical for enzymatic activity. DNA binding stimulates SMYD3 HMTase activity, potentially mediated via the MYND domain.","method":"X-ray crystallography, mutagenesis (Tyr239), biochemical HMTase assay, DNA-binding assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus active-site mutagenesis plus biochemical assays in one study","pmids":["21266482"],"is_preprint":false},{"year":2012,"finding":"SMYD3 catalyzes methylation of histone H4 at lysine 5 (H4K5me); this mark is detected in diverse cell types and is attenuated upon SMYD3 depletion. SMYD3-driven cancer cell phenotypes require its enzymatic activity.","method":"Mass spectrometry, immunoblot with H4K5me-specific antibody, siRNA knockdown, cancer cell phenotype assays","journal":"Epigenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS identification plus antibody validation plus functional knockdown, single lab","pmids":["22419068"],"is_preprint":false},{"year":2014,"finding":"SMYD3 methylates MAP3K2 (MEKK2) at lysine 260, potentiating Ras/Raf/MEK/ERK signaling. The PP2A phosphatase complex binds MAP3K2 and this interaction is blocked by SMYD3-mediated methylation, releasing MAP3K2 from negative regulation. Abrogating SMYD3 catalytic activity inhibits Ras-driven pancreatic and lung adenocarcinoma development in mouse models.","method":"Protein array substrate identification, in vitro methyltransferase assay, Co-IP, mouse cancer models (Kras-driven), MEK inhibitor synergy assay, site-directed mutagenesis (K260)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro reconstitution, mutagenesis, Co-IP of PP2A displacement, in vivo mouse models, replicated by subsequent structural studies","pmids":["24847881"],"is_preprint":false},{"year":2015,"finding":"The C-terminal TPR-like domain of SMYD3 mediates physical interaction with HSP90; this interaction is required for basal HMTase activity and for HSP90-enhanced enzyme activity. Loss of SMYD3-HSP90 interaction causes SMYD3 mislocalization within the nucleus and loss of chromatin association, reducing SMYD3-mediated cell proliferation.","method":"Co-immunoprecipitation, domain-deletion mutagenesis, chromatin fractionation, HMTase assay, cell proliferation assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, mutagenesis, fractionation, single lab","pmids":["25738358"],"is_preprint":false},{"year":2015,"finding":"SMYD3 functions as a coactivator of estrogen receptor alpha (ERα); it directly interacts with the ligand-binding domain of ERα and is recruited to ER target gene promoters upon estrogen stimulation, where it catalyzes H3K4 di- and trimethylation. SMYD3 knockdown abolishes ER-regulated transcription.","method":"Co-immunoprecipitation, ChIP assay, siRNA knockdown, luciferase reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of direct interaction, ChIP evidence of recruitment and H3K4me mark, siRNA functional knockdown, single lab","pmids":["19509295"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of SMYD3 co-crystallized with VEGFR1 and MAP3K2 peptides reveal that a phenylalanine at the -2 position of MAP3K2 fits into a shallow hydrophobic pocket on SMYD3, explaining MAP3K2's preference as a substrate over VEGFR1. SMYD3 follows a partially processive mechanism. The inhibitor GSK2807 (Ki=14 nM) bridges the SAM-binding and substrate lysine tunnel pockets.","method":"X-ray co-crystal structures, kinetic characterization, inhibitor design and structural validation","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple co-crystal structures plus kinetic mechanistic characterization in one study","pmids":["27066749"],"is_preprint":false},{"year":2016,"finding":"Co-crystal structures of SMYD3 with VEGFR1 and MAP3K2 peptides provide structural basis for substrate preference: the phenylalanine at -2 of MAP3K2 confers robust catalytic activity whereas VEGFR1 lysine location in a folded kinase domain requires unfavorable conformational rearrangement, explaining weak activity toward VEGFR1.","method":"X-ray crystallography, in vitro biochemical methylation assays with peptide substrates","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures plus quantitative biochemical assays, independently consistent with Van Aller 2016","pmids":["26929412"],"is_preprint":false},{"year":2016,"finding":"SMYD3 methylates histone H2A.Z.1 at lysine 101 (H2A.Z.1K101me2), increasing its stability by preventing binding to the removal chaperone ANP32E and facilitating interaction with histone H3. This methylation event activates cyclin A1 expression at its promoter and drives G1-S progression.","method":"In vitro methyltransferase assay, mass spectrometry, Co-IP, microarray, ChIP assay, mutagenesis, mouse tumor model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro assay plus MS plus ChIP plus mutagenesis rescue, single lab","pmids":["27569210"],"is_preprint":false},{"year":2016,"finding":"SMYD3 methylates AKT1 at lysine 14 in the PH domain both in vitro and in vivo; this methylation is required for AKT1 phosphorylation at threonine 308 (activation) and for plasma membrane accumulation of AKT1. SMYD3 knockdown or pharmacological inhibition attenuates T308 phosphorylation.","method":"In vitro methyltransferase assay, site-directed mutagenesis (K14 substitution), subcellular fractionation/membrane localization assay, siRNA knockdown, SMYD3 inhibitor treatment, cell growth assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro assay, mutagenesis, localization and phosphorylation readouts, single lab","pmids":["27626683"],"is_preprint":false},{"year":2016,"finding":"In mouse liver and colon cancer models, SMYD3 is localized in the nucleus, interacts with H3K4me3-modified histone tails, and is recruited to core promoter regions. SMYD3 binding increases RNA polymerase II density and transcriptional output of a specific set of oncogenes and cell proliferation genes, including Myc and Ctnnb1. Smyd3 knockout mice are resistant to chemically induced liver and colon cancer.","method":"ChIP-seq, RNA-seq, conditional Smyd3 knockout mouse model with chemical carcinogenesis, Co-IP with H3K4me3 tails","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq plus RNA-seq plus in vivo knockout mouse model, multiple orthogonal methods","pmids":["26908355"],"is_preprint":false},{"year":2013,"finding":"SMYD3 methyltransferase targets myostatin and c-Met gene regulatory regions in skeletal muscle cells and recruits the bromodomain protein BRD4 through protein-protein interaction. BRD4 recruitment by SMYD3 facilitates engagement of the pause-release factor p-TEFb and elongation of Ser2-phosphorylated RNA Pol II, activating myostatin and c-Met transcription. SMYD3 depletion prevents dexamethasone-induced muscle atrophy in mice.","method":"ChIP assay, Co-IP (SMYD3-BRD4 interaction), siRNA knockdown, JQ1 BRD4 inhibitor, in vivo mouse dexamethasone atrophy model","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP, ChIP, pharmacological validation with JQ1, in vivo mouse model, multiple methods","pmids":["23752591"],"is_preprint":false},{"year":2015,"finding":"SMYD3 interacts with positive coactivator PC4; this interaction is mutually required for SMYD3 and PC4 co-recruitment to target gene promoters and for SMYD3-mediated H3K4me3 and target gene expression. PC4 depletion abolishes SMYD3-driven H3K4me3 and oncogenic transcription.","method":"Co-immunoprecipitation, ChIP assay, siRNA knockdown of PC4, artificial tethering of SMYD3 mutant","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus ChIP plus genetic epistasis by siRNA, single lab","pmids":["26350217"],"is_preprint":false},{"year":2019,"finding":"SMYD3 directly interacts with SMAD3 (via Co-IP) and is indispensable for SMAD3 association to chromatin at EMT gene regulatory regions during TGFβ signaling. SMYD3 is not required for SMAD2/3 phosphorylation or nuclear translocation but is required for the final chromatin recruitment step. Pharmacological SMYD3 blockade reduces TGFβ-induced mesenchymal gene transcription and invasion in vivo (zebrafish xenograft).","method":"Co-immunoprecipitation, ChIP assay, siRNA/pharmacological inhibitor (BCI121), zebrafish xenograft invasion assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, in vivo xenograft, single lab","pmids":["30544196"],"is_preprint":false},{"year":2017,"finding":"SMYD3 trimethylates HER2 at lysine 175; this methylation enhances HER2 homodimerization, and the K175A substitution reduces homodimer formation and autophosphorylation. SMYD3 knockdown attenuates HER2 autophosphorylation in breast cancer cells.","method":"In vitro methyltransferase assay, site-directed mutagenesis (K175A), Co-IP homodimerization assay, siRNA knockdown, phosphorylation immunoblot","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro assay, mutagenesis, Co-IP, cellular phosphorylation assay, single lab","pmids":["28639750"],"is_preprint":false},{"year":2022,"finding":"SMYD3 methylates RNF113A, and this methylation impairs RNF113A's interaction with the phosphatase PP4, thereby controlling RNF113A phosphorylation levels; the methylation-phosphorylation cross-talk maintains RNF113A E3 ligase activity required for alkylation damage response. SMYD3 inhibition restores SCLC vulnerability to alkylating chemotherapy.","method":"In vitro methyltransferase assay, Co-IP (RNF113A-PP4 interaction assay), pharmacological SMYD3 inhibition, chemosensitivity assay, in vivo SCLC model","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro enzymatic assay, Co-IP mechanistic readout, in vivo model, multiple orthogonal approaches in one study","pmids":["35819319"],"is_preprint":false},{"year":2020,"finding":"SMYD3 phosphorylation by ATM kinase enables formation of a multiprotein complex including ATM, SMYD3, CHK2, and BRCA2, which is required for RAD51 loading at DNA double-strand break sites and completion of homologous recombination. SMYD3 pharmacological inhibition sensitizes HR-proficient cancer cells to PARP inhibitors.","method":"Co-IP of ATM-SMYD3-CHK2-BRCA2 complex, RAD51 foci assay, SMYD3 inhibitor + PARP inhibitor synthetic lethality assay, domain mapping using SMYD3 mutant variant","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of multi-protein complex, functional RAD51 loading assay, pharmacological synthetic lethality, single lab","pmids":["33205017"],"is_preprint":false},{"year":2010,"finding":"SMYD3 directly interacts with HTLV-1 Tax protein via the C-terminal 180 amino acids of SMYD3; SMYD3 dominates the subcellular localization of Tax, promoting cytoplasmic retention of Tax and enhancing Tax-mediated NF-κB activation. SMYD3 knockdown attenuates NF-κB activation by cytoplasmic Tax.","method":"Co-immunoprecipitation, in vitro pull-down, co-localization microscopy, domain-deletion mutagenesis, NF-κB reporter assay, shRNA knockdown","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus in vitro pull-down plus functional reporter assay, single lab","pmids":["21054678"],"is_preprint":false},{"year":2014,"finding":"SMYD3 interacts with HCV NS5A via SMYD3's MYND domain and NS5A domain III (mapped by mutagenesis). SMYD3 overexpression decreases intracellular and extracellular HCV virus titers without affecting viral RNA replication, indicating SMYD3 negatively affects particle production in an NS5A-dependent manner.","method":"Co-immunoprecipitation, co-localization, mutagenesis of MYND domain and NS5A domain III, virus titer assay, RNA replication assay","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping by mutagenesis plus functional titer readout, single lab","pmids":["25092459"],"is_preprint":false},{"year":2019,"finding":"SMYD3 is recruited by Ebola virus nucleoprotein (NP) to viral inclusion bodies; SMYD3 depletion suppresses EBOV mRNA production and SMYD3 promotes NP-VP30 interaction in a dose-dependent manner, supporting viral transcription.","method":"Co-immunoprecipitation (SMYD3-NP), mass spectrometry, minigenome system, siRNA knockdown, co-localization, NP-VP30 interaction assay","journal":"Emerging microbes & infections","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus MS identification plus functional minigenome assay, single lab","pmids":["31516086"],"is_preprint":false},{"year":2007,"finding":"SMYD3 occupies its binding motifs on the hTERT promoter and is required for H3K4 trimethylation at that locus. SMYD3 knockdown abolishes H3K4me3 at the hTERT promoter, attenuates c-MYC and Sp1 occupancy, reduces histone H3 acetylation, and decreases hTERT mRNA and telomerase activity.","method":"ChIP assay, siRNA knockdown, quantitative RT-PCR, telomerase activity assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with histone marks, siRNA functional knockdown, multiple readouts, single lab","pmids":["17363582"],"is_preprint":false},{"year":2020,"finding":"SMYD3 directly binds the promoter region of Cdkn1a (p21), increases H3K4me3 at that locus, and elevates p21 expression, driving endothelial cell senescence-associated phenotypes. Smyd3 knockout mice are protected from Ang II-induced vascular senescence.","method":"ChIP assay, Smyd3 knockout mice, Ang II vascular senescence model, immunoblot, siRNA knockdown","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP direct promoter binding plus in vivo knockout model, single lab","pmids":["32779886"],"is_preprint":false},{"year":2020,"finding":"SMYD3 binds the promoter of PARP16 and increases H3K4me3 at that locus to activate PARP16 transcription. SMYD3-driven PARP16 upregulation activates ER stress/UPR and promotes smooth muscle cell proliferation and neointimal hyperplasia. Knockdown of either SMYD3 or PARP16 impedes ER stress and SMC proliferation.","method":"ChIP-seq, ChIP assay, siRNA knockdown, overexpression, in vivo neointimal hyperplasia model","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus ChIP plus in vivo model, single lab","pmids":["34094832"],"is_preprint":false},{"year":2023,"finding":"SMYD3 methyltransferase is elevated in Alzheimer's disease PFC and P301S Tau mouse PFC; SMYD3-mediated H3K4me3 upregulates Fbxo2 (E3 ubiquitin ligase), which increases ubiquitination and degradation of NMDAR subunit NR1. SMYD3 inhibition rescues synaptic NMDAR function and cognitive deficits in P301S Tau mice.","method":"SMYD3 inhibitor (BCI-121) treatment, electrophysiology, behavioral assays, ChIP assay, Fbxo2 knockdown, ubiquitination assay in mouse PFC","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP mechanistic link plus ubiquitination assay plus in vivo pharmacological rescue plus genetic epistasis (Fbxo2 knockdown), multiple orthogonal methods","pmids":["36609445"],"is_preprint":false},{"year":2023,"finding":"SMYD3 methylates EZH2 at K421; this methylation accelerates EZH2 ubiquitin-proteasome degradation. Cells harboring non-methylated EZH2 (K421 mutant) show enhanced gastric cancer metastasis, indicating SMYD3-EZH2 methylation restricts rather than promotes metastasis via EZH2 stability.","method":"In vitro methyltransferase assay, site-directed mutagenesis (K421), ubiquitination assay, soft agar colony formation, in vivo metastasis model","journal":"Cancer gene therapy","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro assay plus mutagenesis plus functional cancer assays, single lab","pmids":["36127410"],"is_preprint":false},{"year":2023,"finding":"SMYD3 depletion in HPV-negative HNSCC induces upregulation of type I interferon response and antigen presentation genes. Mechanistically, SMYD3 binds and activates UHRF1 transcription; UHRF1 reads H3K9me3 at immune gene promoters, recruits DNMT1, and silences their expression. SMYD3 also deposits H4K20me3 intragentically to maintain repression of immune-related genes. In vivo, Smyd3 depletion increases CD8+ T cell infiltration and sensitivity to anti-PD-1 therapy.","method":"ChIP-seq, RNA-seq, siRNA/shRNA knockdown, in vivo syngeneic mouse model with anti-PD-1 treatment, UHRF1 epistasis experiments","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq mechanistic pathway plus RNA-seq plus genetic epistasis (UHRF1) plus in vivo immune model, multiple orthogonal methods","pmids":["37463106"],"is_preprint":false},{"year":2023,"finding":"SMYD3-dependent MAP3K2 methylation promotes EMT-associated behaviors and vimentin upregulation in prostate cancer cells. A positive feedback loop exists whereby SMYD3-MAP3K2-MAPK signaling continually promotes high SMYD3 levels. Both in vitro and xenograft models show SMYD3 catalytic activity is required for these tumor-associated phenotypes.","method":"In vitro methyltransferase assay, mutagenesis, siRNA knockdown, mouse xenograft model, EMT marker immunoblot","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro assay plus mutagenesis plus in vivo xenograft, single lab","pmids":["37976356"],"is_preprint":false},{"year":2020,"finding":"SMYD3 nucleo-cytoplasmic localization is regulated by cell geometry (shape and aspect ratio) via cytoskeletal acto-myosin signaling; elongated shapes reduce nuclear SMYD3 import. Nuclear vs. cytoplasmic distribution of SMYD3 correlates with compartment-specific lysine trimethylation (Kme3) levels, consistent with SMYD3 having both nuclear and cytoplasmic substrates.","method":"Live imaging, pharmacological acto-myosin disruption, immunofluorescence with compartment-specific methylation readout","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization imaging with cytoskeletal perturbation and methylation readout, single lab","pmids":["33244033"],"is_preprint":false},{"year":2019,"finding":"SMYD3 directly interacts with ANKHD1 (identified by mass spectrometry of H3K4me3 pulldown from SMYD3-overexpressing cells). ANKHD1 is required for SMYD3-mediated activation of SLUG gene transcription through H3K4me3 enrichment at the SLUG promoter; ANKHD1 knockdown attenuates the pro-migratory and pro-invasive effects of SMYD3.","method":"Mass spectrometry, Co-IP, ChIP (H3K4me3 at SLUG promoter), EMSA, siRNA epistasis (ANKHD1), migration/invasion assay","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS identification, Co-IP, ChIP, genetic epistasis by siRNA, single lab","pmids":["30646949"],"is_preprint":false},{"year":2019,"finding":"SMYD3 interacts with p53 directly via the post-SET domain; this interaction promotes p53 ubiquitination and proteasomal degradation independent of MDM2. SMYD3 interacts with the ubiquitin-conjugating enzyme UBE2R2, forming a SMYD3-UBE2R2-p53 complex that ubiquitinates p53 at lysines 381, 382, and 386. SMYD3 promotes p53 translocation from nucleus to cytoplasm.","method":"Co-immunoprecipitation, mass spectrometry, ubiquitination assay, domain-deletion (post-SET) mapping, site-directed mutagenesis of p53 lysines, subcellular fractionation","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus MS plus mutagenesis plus functional ubiquitination assay, single lab","pmids":["31002112"],"is_preprint":false},{"year":2011,"finding":"Smyd3 knockdown in zebrafish embryos using morpholino antisense oligonucleotides causes pericardial edema, trunk structure defects, and abnormal expression of heart-chamber markers (cmlc2, amhc, vmhc) and myogenic regulatory factors (myod, myog), establishing a role for Smyd3 in cardiac and skeletal muscle development.","method":"Morpholino knockdown in zebrafish, whole-mount in situ hybridization for developmental markers","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino loss-of-function with specific developmental marker readout, single lab in zebrafish","pmids":["21887258"],"is_preprint":false}],"current_model":"SMYD3 is a SET domain-containing lysine methyltransferase that operates in both the nucleus and cytoplasm: in the nucleus it methylates H3K4 (mono-, di-, trimethylation), H4K5, H4K20, and H2A.Z.1-K101 to activate or repress specific gene programs (including oncogenes, cell-cycle regulators, and immune response genes), interacting with RNA Pol II, BRD4, PC4, SMAD3, and ANKHD1; in the cytoplasm it methylates non-histone substrates including MAP3K2-K260 (releasing it from PP2A inhibition to potentiate Ras/ERK signaling), VEGFR1-K831 (enhancing kinase activity), AKT1-K14 (promoting membrane localization and T308 phosphorylation), HER2-K175 (promoting homodimerization and autophosphorylation), RNF113A (modulating PP4 interaction and alkylation damage response), and EZH2-K421 (promoting its degradation); its enzymatic activity is stimulated by HSP90 binding to its C-terminal TPR-like domain and by N-terminal cleavage, and its nucleo-cytoplasmic distribution is regulated by cytoskeletal/mechanical cues."},"narrative":{"mechanistic_narrative":"SMYD3 is a SET-domain lysine methyltransferase that controls oncogenic and stress-response gene programs by acting on both chromatin and cytoplasmic signaling substrates [PMID:15235609, PMID:24847881]. In the nucleus, its SET domain methylates histone H3K4 (including di- and trimethylation), H4K5, and histone variant H2A.Z.1 at K101, the latter stabilizing the nucleosome against the ANP32E removal chaperone to activate cyclin A1 and drive G1-S progression [PMID:15235609, PMID:22419068, PMID:27569210]. SMYD3 is recruited to specific promoters through interaction with RNA polymerase II, the coactivator PC4, BRD4 (which engages p-TEFb to release paused Pol II), the estrogen receptor, SMAD3 during TGFβ-driven EMT, and ANKHD1, thereby transactivating oncogenes, cell-cycle genes, and EMT regulators including Myc, Ctnnb1, hTERT, and SLUG [PMID:19509295, PMID:26908355, PMID:23752591, PMID:26350217, PMID:30544196, PMID:17363582, PMID:30646949]. Beyond gene activation it also enforces gene silencing, activating UHRF1 transcription and depositing intragenic H4K20me3 to repress type I interferon and antigen-presentation genes, restraining antitumor immunity [PMID:37463106]. In the cytoplasm SMYD3 methylates non-histone substrates to amplify kinase signaling: MAP3K2-K260 methylation blocks PP2A binding to potentiate Ras/Raf/MEK/ERK signaling and Ras-driven tumorigenesis, AKT1-K14 promotes T308 phosphorylation and membrane localization, and HER2-K175 trimethylation promotes homodimerization and autophosphorylation [PMID:24847881, PMID:27626683, PMID:28639750]. SMYD3 additionally couples to the DNA damage and chemoresistance machinery, methylating RNF113A to sustain its E3 ligase activity in the alkylation response and forming an ATM–CHK2–BRCA2 complex required for RAD51 loading in homologous recombination [PMID:35819319, PMID:33205017]. Structurally, a C-terminal TPR domain together with the SET and post-SET domains forms a deep substrate-binding pocket; HSP90 binding to this TPR domain and N-terminal cleavage stimulate catalytic activity, while DNA binding further enhances HMTase activity [PMID:21266482, PMID:17998933, PMID:25738358]. Genetic ablation establishes a causal in vivo requirement for SMYD3 across chemically induced liver/colon cancer, vascular senescence and neointimal hyperplasia, muscle atrophy, and Tau-driven cognitive decline [PMID:26908355, PMID:23752591, PMID:32779886, PMID:34094832, PMID:36609445].","teleology":[{"year":2004,"claim":"Established SMYD3 as a sequence-specific transcriptional activator with intrinsic H3K4 methyltransferase activity, defining its founding role in oncogene expression.","evidence":"In vitro HMTase assay, Co-IP with Pol II via HELZ, promoter motif binding, siRNA proliferation readout","pmids":["15235609"],"confidence":"High","gaps":["Did not resolve full substrate spectrum beyond H3K4","Mechanism of HSP90 stimulation not yet structurally defined"]},{"year":2007,"claim":"Showed SMYD3 acts beyond chromatin by methylating a receptor tyrosine kinase, and mapped intrinsic negative regulation by its N-terminus.","evidence":"In vitro methylation with MS site mapping (VEGFR1-K831), N-terminal truncation/mutagenesis with HMTase assay and HSP90 Co-IP","pmids":["18006819","17998933"],"confidence":"Medium","gaps":["VEGFR1 was later shown to be a weak substrate structurally","Physiological trigger for N-terminal cleavage unknown"]},{"year":2011,"claim":"Provided the first full-length structure, revealing the TPR-SET-postSET substrate pocket and that DNA binding stimulates catalysis.","evidence":"X-ray crystallography with SAH, Tyr239 active-site mutagenesis, DNA-binding HMTase assay","pmids":["21266482"],"confidence":"High","gaps":["Did not capture peptide substrates in the pocket","MYND-mediated DNA binding mechanism inferred not proven"]},{"year":2014,"claim":"Defined the central oncogenic non-histone mechanism: MAP3K2-K260 methylation displaces PP2A to potentiate Ras/ERK signaling and drive tumorigenesis in vivo.","evidence":"Protein-array substrate ID, in vitro methylation, Co-IP of PP2A displacement, Kras-driven mouse cancer models, MEK-inhibitor synergy","pmids":["24847881"],"confidence":"High","gaps":["Did not quantify relative flux through histone versus MAP3K2 axes","Reader/effector of K260me beyond PP2A not detailed"]},{"year":2016,"claim":"Co-crystal structures explained substrate selectivity (-2 phenylalanine of MAP3K2) over VEGFR1 and validated a tractable active-site inhibitor.","evidence":"Co-crystal structures with VEGFR1/MAP3K2 peptides, kinetic analysis, GSK2807 inhibitor characterization","pmids":["27066749","26929412"],"confidence":"High","gaps":["Structural basis for histone versus non-histone preference not resolved","Processivity implications for cellular output untested"]},{"year":2016,"claim":"Expanded the nuclear and cytoplasmic substrate repertoire to a histone variant and a survival kinase, linking SMYD3 directly to cell-cycle progression and AKT activation.","evidence":"In vitro methylation + MS (H2A.Z.1-K101, AKT1-K14), Co-IP with ANP32E/H3, mutagenesis, membrane fractionation, ChIP, mouse tumor model","pmids":["27569210","27626683"],"confidence":"Medium","gaps":["Single-lab substrate identifications without independent replication","Stoichiometry of these marks in vivo unclear"]},{"year":2017,"claim":"Extended kinase-activating methylation to HER2, coupling SMYD3 to receptor dimerization in breast cancer.","evidence":"In vitro methylation, K175A mutagenesis, Co-IP homodimerization, siRNA, phospho-immunoblot","pmids":["28639750"],"confidence":"Medium","gaps":["Direct K175me detection in patient tumors not shown","Mechanism linking methylation to dimer interface undefined"]},{"year":2020,"claim":"Connected SMYD3 to the homologous recombination machinery and to mechanical control of its compartmental localization.","evidence":"Co-IP of ATM-SMYD3-CHK2-BRCA2 complex, RAD51 foci, PARPi synthetic lethality; live imaging with acto-myosin perturbation and compartment-specific Kme3","pmids":["33205017","33244033"],"confidence":"Medium","gaps":["Whether SMYD3 methylation activity (vs scaffolding) drives HR is unresolved","Cytoplasmic Kme3 substrates not individually mapped in the geometry study"]},{"year":2022,"claim":"Showed SMYD3 methylation-phosphorylation cross-talk on RNF113A governs alkylation-damage response and chemosensitivity.","evidence":"In vitro methylation, RNF113A-PP4 Co-IP, pharmacological SMYD3 inhibition, chemosensitivity and in vivo SCLC model","pmids":["35819319"],"confidence":"High","gaps":["Methylated residue(s) on RNF113A not specified here","Generality across alkylating agents not fully mapped"]},{"year":2023,"claim":"Revealed dual transcriptional logic — silencing immune genes via UHRF1/H4K20me3 and tuning substrate stability via EZH2 methylation — and a neurological role through Fbxo2-NMDAR control.","evidence":"ChIP-seq/RNA-seq with UHRF1 epistasis and anti-PD-1 model; EZH2-K421 methylation/ubiquitination/metastasis assays; Tau-mouse ChIP, ubiquitination, electrophysiology and behavior","pmids":["37463106","36127410","36609445"],"confidence":"High","gaps":["How SMYD3 switches between activating and repressive chromatin states is unresolved","EZH2-K421 degradation places SMYD3 as metastasis-restraining, contrasting its oncogenic roles — context determinants unknown"]},{"year":null,"claim":"It remains unresolved what determines the partitioning of SMYD3 between its histone-modifying, transcriptional-scaffolding, and cytoplasmic kinase-methylating functions in a given cell, and which of its many substrates dominate in each disease context.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating localization control with substrate choice","Relative contribution of catalytic vs scaffolding activity per pathway untested","Substrate hierarchy in vivo unquantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5,11,16,17]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[0,4,10,12]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,8]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,3]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12,13,27]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[13,14,30]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[12,29]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5,11,29]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[6,12]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,12,13,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,11,16,28]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[10]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[17,18]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[10,12,27]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[27]}],"complexes":["ATM-SMYD3-CHK2-BRCA2 complex","SMYD3-UBE2R2-p53 complex","RNA Pol II complex (via HELZ)"],"partners":["HSP90","BRD4","PC4","SMAD3","ANKHD1","MAP3K2","EZH2","RNF113A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H7B4","full_name":"Histone-lysine N-methyltransferase SMYD3","aliases":["SET and MYND domain-containing protein 3","Zinc finger MYND domain-containing protein 1"],"length_aa":428,"mass_kda":49.1,"function":"Histone methyltransferase. Specifically methylates 'Lys-4' of histone H3, inducing di- and tri-methylation, but not monomethylation (PubMed:15235609, PubMed:22419068). Also methylates 'Lys-5' of histone H4 (PubMed:22419068). Plays an important role in transcriptional activation as a member of an RNA polymerase complex (PubMed:15235609). Binds DNA containing 5'-CCCTCC-3' or 5'-GAGGGG-3' sequences (PubMed:15235609)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H7B4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMYD3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SMYD3","total_profiled":1310},"omim":[{"mim_id":"609487","title":"MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2; MAP3K2","url":"https://www.omim.org/entry/609487"},{"mim_id":"608783","title":"SET AND MYND DOMAIN-CONTAINING PROTEIN 3; SMYD3","url":"https://www.omim.org/entry/608783"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SMYD3"},"hgnc":{"alias_symbol":["KMT3E"],"prev_symbol":["ZNFN3A1","ZMYND1"]},"alphafold":{"accession":"Q9H7B4","domains":[{"cath_id":"2.170.270.10","chopping":"2-36_199-271","consensus_level":"medium","plddt":97.9144,"start":2,"end":271},{"cath_id":"1.10.220.160","chopping":"40-183","consensus_level":"high","plddt":97.1915,"start":40,"end":183},{"cath_id":"1.25.40.970","chopping":"277-354","consensus_level":"medium","plddt":96.6767,"start":277,"end":354},{"cath_id":"1.25.40.10","chopping":"363-428","consensus_level":"medium","plddt":97.527,"start":363,"end":428}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H7B4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H7B4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H7B4-F1-predicted_aligned_error_v6.png","plddt_mean":97.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMYD3","jax_strain_url":"https://www.jax.org/strain/search?query=SMYD3"},"sequence":{"accession":"Q9H7B4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H7B4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H7B4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H7B4"}},"corpus_meta":[{"pmid":"15235609","id":"PMC_15235609","title":"SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.","date":"2004","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15235609","citation_count":595,"is_preprint":false},{"pmid":"24847881","id":"PMC_24847881","title":"SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24847881","citation_count":319,"is_preprint":false},{"pmid":"16441421","id":"PMC_16441421","title":"Enhanced SMYD3 expression is essential for the growth of breast cancer cells.","date":"2006","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/16441421","citation_count":215,"is_preprint":false},{"pmid":"20725992","id":"PMC_20725992","title":"Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.","date":"2010","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20725992","citation_count":172,"is_preprint":false},{"pmid":"22194464","id":"PMC_22194464","title":"SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22194464","citation_count":149,"is_preprint":false},{"pmid":"22419068","id":"PMC_22419068","title":"Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.","date":"2012","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22419068","citation_count":148,"is_preprint":false},{"pmid":"18006819","id":"PMC_18006819","title":"The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18006819","citation_count":143,"is_preprint":false},{"pmid":"26908355","id":"PMC_26908355","title":"Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.","date":"2016","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/26908355","citation_count":121,"is_preprint":false},{"pmid":"25728514","id":"PMC_25728514","title":"A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25728514","citation_count":98,"is_preprint":false},{"pmid":"16155568","id":"PMC_16155568","title":"A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.","date":"2005","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16155568","citation_count":97,"is_preprint":false},{"pmid":"17363582","id":"PMC_17363582","title":"The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17363582","citation_count":93,"is_preprint":false},{"pmid":"22819820","id":"PMC_22819820","title":"Epigenetic regulation of miR-124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.","date":"2012","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/22819820","citation_count":87,"is_preprint":false},{"pmid":"29253179","id":"PMC_29253179","title":"The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29253179","citation_count":85,"is_preprint":false},{"pmid":"19509295","id":"PMC_19509295","title":"Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19509295","citation_count":81,"is_preprint":false},{"pmid":"30544196","id":"PMC_30544196","title":"SMYD3 promotes the epithelial-mesenchymal transition in breast cancer.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30544196","citation_count":75,"is_preprint":false},{"pmid":"23752591","id":"PMC_23752591","title":"The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy.","date":"2013","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/23752591","citation_count":70,"is_preprint":false},{"pmid":"26350217","id":"PMC_26350217","title":"Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26350217","citation_count":69,"is_preprint":false},{"pmid":"24174655","id":"PMC_24174655","title":"SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.","date":"2013","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/24174655","citation_count":65,"is_preprint":false},{"pmid":"25980436","id":"PMC_25980436","title":"SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25980436","citation_count":65,"is_preprint":false},{"pmid":"25669152","id":"PMC_25669152","title":"Epigenetic control of Foxp3 by SMYD3 H3K4 histone methyltransferase controls iTreg development and regulates pathogenic T-cell responses during pulmonary viral infection.","date":"2015","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25669152","citation_count":65,"is_preprint":false},{"pmid":"21887258","id":"PMC_21887258","title":"Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21887258","citation_count":61,"is_preprint":false},{"pmid":"31935919","id":"PMC_31935919","title":"SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31935919","citation_count":59,"is_preprint":false},{"pmid":"21266482","id":"PMC_21266482","title":"Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21266482","citation_count":58,"is_preprint":false},{"pmid":"27554136","id":"PMC_27554136","title":"Smyd3-associated regulatory pathways in cancer.","date":"2016","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/27554136","citation_count":56,"is_preprint":false},{"pmid":"33637115","id":"PMC_33637115","title":"SMYD3: a regulator of epigenetic and signaling pathways in cancer.","date":"2021","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33637115","citation_count":56,"is_preprint":false},{"pmid":"30842588","id":"PMC_30842588","title":"Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30842588","citation_count":56,"is_preprint":false},{"pmid":"19321255","id":"PMC_19321255","title":"Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.","date":"2009","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19321255","citation_count":55,"is_preprint":false},{"pmid":"24189459","id":"PMC_24189459","title":"Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/24189459","citation_count":53,"is_preprint":false},{"pmid":"17998933","id":"PMC_17998933","title":"Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17998933","citation_count":53,"is_preprint":false},{"pmid":"29746925","id":"PMC_29746925","title":"SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29746925","citation_count":52,"is_preprint":false},{"pmid":"29856759","id":"PMC_29856759","title":"Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29856759","citation_count":51,"is_preprint":false},{"pmid":"26676636","id":"PMC_26676636","title":"Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26676636","citation_count":49,"is_preprint":false},{"pmid":"27569210","id":"PMC_27569210","title":"SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27569210","citation_count":49,"is_preprint":false},{"pmid":"27066749","id":"PMC_27066749","title":"Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.","date":"2016","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/27066749","citation_count":49,"is_preprint":false},{"pmid":"18452649","id":"PMC_18452649","title":"Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro.","date":"2008","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/18452649","citation_count":48,"is_preprint":false},{"pmid":"25738358","id":"PMC_25738358","title":"C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25738358","citation_count":47,"is_preprint":false},{"pmid":"27626683","id":"PMC_27626683","title":"SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27626683","citation_count":45,"is_preprint":false},{"pmid":"26980013","id":"PMC_26980013","title":"SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.","date":"2016","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26980013","citation_count":43,"is_preprint":false},{"pmid":"20957523","id":"PMC_20957523","title":"Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.","date":"2010","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20957523","citation_count":42,"is_preprint":false},{"pmid":"32779886","id":"PMC_32779886","title":"Histone methyltransferase Smyd3 is a new regulator for vascular senescence.","date":"2020","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/32779886","citation_count":41,"is_preprint":false},{"pmid":"31417652","id":"PMC_31417652","title":"Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.","date":"2019","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31417652","citation_count":40,"is_preprint":false},{"pmid":"31503345","id":"PMC_31503345","title":"SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31503345","citation_count":37,"is_preprint":false},{"pmid":"17963297","id":"PMC_17963297","title":"Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.","date":"2007","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17963297","citation_count":37,"is_preprint":false},{"pmid":"28957646","id":"PMC_28957646","title":"A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1.","date":"2017","source":"SLAS discovery : advancing life sciences R & D","url":"https://pubmed.ncbi.nlm.nih.gov/28957646","citation_count":37,"is_preprint":false},{"pmid":"33542221","id":"PMC_33542221","title":"LncRNA LTSCCAT promotes tongue squamous cell carcinoma metastasis via targeting the miR-103a-2-5p/SMYD3/TWIST1 axis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33542221","citation_count":35,"is_preprint":false},{"pmid":"30646949","id":"PMC_30646949","title":"ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30646949","citation_count":34,"is_preprint":false},{"pmid":"26929412","id":"PMC_26929412","title":"Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26929412","citation_count":34,"is_preprint":false},{"pmid":"30998113","id":"PMC_30998113","title":"Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.","date":"2019","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30998113","citation_count":33,"is_preprint":false},{"pmid":"19082926","id":"PMC_19082926","title":"Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.","date":"2008","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19082926","citation_count":33,"is_preprint":false},{"pmid":"28639750","id":"PMC_28639750","title":"Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.","date":"2017","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28639750","citation_count":31,"is_preprint":false},{"pmid":"25382779","id":"PMC_25382779","title":"Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.","date":"2014","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25382779","citation_count":31,"is_preprint":false},{"pmid":"20039369","id":"PMC_20039369","title":"Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.","date":"2010","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/20039369","citation_count":29,"is_preprint":false},{"pmid":"25471787","id":"PMC_25471787","title":"Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.","date":"2014","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25471787","citation_count":29,"is_preprint":false},{"pmid":"31968646","id":"PMC_31968646","title":"Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora.","date":"2020","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/31968646","citation_count":29,"is_preprint":false},{"pmid":"21450690","id":"PMC_21450690","title":"Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.","date":"2011","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/21450690","citation_count":29,"is_preprint":false},{"pmid":"29302370","id":"PMC_29302370","title":"ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.","date":"2017","source":"Journal of gastric cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29302370","citation_count":27,"is_preprint":false},{"pmid":"34094832","id":"PMC_34094832","title":"SMYD3-PARP16 axis accelerates unfolded protein response and mediates neointima formation.","date":"2020","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/34094832","citation_count":26,"is_preprint":false},{"pmid":"36609445","id":"PMC_36609445","title":"Inhibition of histone methyltransferase Smyd3 rescues NMDAR and cognitive deficits in a tauopathy mouse model.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36609445","citation_count":26,"is_preprint":false},{"pmid":"32291411","id":"PMC_32291411","title":"VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32291411","citation_count":26,"is_preprint":false},{"pmid":"35819319","id":"PMC_35819319","title":"SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk.","date":"2022","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35819319","citation_count":25,"is_preprint":false},{"pmid":"37463106","id":"PMC_37463106","title":"SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37463106","citation_count":25,"is_preprint":false},{"pmid":"26790435","id":"PMC_26790435","title":"Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26790435","citation_count":25,"is_preprint":false},{"pmid":"19472189","id":"PMC_19472189","title":"Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells.","date":"2009","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/19472189","citation_count":25,"is_preprint":false},{"pmid":"31441002","id":"PMC_31441002","title":"Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.","date":"2019","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31441002","citation_count":24,"is_preprint":false},{"pmid":"24993551","id":"PMC_24993551","title":"Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24993551","citation_count":24,"is_preprint":false},{"pmid":"29029425","id":"PMC_29029425","title":"MiR-346 suppresses cell proliferation through SMYD3 dependent approach in hepatocellular carcinoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29029425","citation_count":24,"is_preprint":false},{"pmid":"34301921","id":"PMC_34301921","title":"SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34301921","citation_count":23,"is_preprint":false},{"pmid":"31223458","id":"PMC_31223458","title":"Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.","date":"2019","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/31223458","citation_count":23,"is_preprint":false},{"pmid":"31002112","id":"PMC_31002112","title":"SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination.","date":"2019","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31002112","citation_count":22,"is_preprint":false},{"pmid":"21054678","id":"PMC_21054678","title":"SMYD3 interacts with HTLV-1 Tax and regulates subcellular localization of Tax.","date":"2010","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/21054678","citation_count":22,"is_preprint":false},{"pmid":"31516086","id":"PMC_31516086","title":"Host factor SMYD3 is recruited by Ebola virus nucleoprotein to facilitate viral mRNA transcription.","date":"2019","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/31516086","citation_count":22,"is_preprint":false},{"pmid":"18294291","id":"PMC_18294291","title":"Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/18294291","citation_count":22,"is_preprint":false},{"pmid":"31754141","id":"PMC_31754141","title":"The SMYD3 methyltransferase promotes myogenesis by activating the myogenin regulatory network.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31754141","citation_count":21,"is_preprint":false},{"pmid":"25918436","id":"PMC_25918436","title":"Histone methyltransferase Smyd3 regulates early embryonic lineage commitment in mice.","date":"2015","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25918436","citation_count":21,"is_preprint":false},{"pmid":"34154424","id":"PMC_34154424","title":"Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.","date":"2021","source":"SLAS discovery : advancing life sciences R & D","url":"https://pubmed.ncbi.nlm.nih.gov/34154424","citation_count":21,"is_preprint":false},{"pmid":"33205017","id":"PMC_33205017","title":"Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33205017","citation_count":20,"is_preprint":false},{"pmid":"37237385","id":"PMC_37237385","title":"Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.","date":"2023","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/37237385","citation_count":19,"is_preprint":false},{"pmid":"36330911","id":"PMC_36330911","title":"The SMYD3-MTHFD1L-formate metabolic regulatory axis mediates mitophagy to inhibit M1 polarization in macrophages.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36330911","citation_count":18,"is_preprint":false},{"pmid":"25092459","id":"PMC_25092459","title":"The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production.","date":"2014","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/25092459","citation_count":18,"is_preprint":false},{"pmid":"33144524","id":"PMC_33144524","title":"Smyd3-PARP16 axis accelerates unfolded protein response and vascular aging.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33144524","citation_count":17,"is_preprint":false},{"pmid":"33244033","id":"PMC_33244033","title":"Cell geometry and the cytoskeleton impact the nucleo-cytoplasmic localisation of the SMYD3 methyltransferase.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33244033","citation_count":17,"is_preprint":false},{"pmid":"37386026","id":"PMC_37386026","title":"SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37386026","citation_count":17,"is_preprint":false},{"pmid":"34621667","id":"PMC_34621667","title":"A SMYD3/ITGB6/TGFβ1 Positive Feedback Loop Promotes the Invasion and Adhesion of Ovarian Cancer Spheroids.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34621667","citation_count":17,"is_preprint":false},{"pmid":"36116234","id":"PMC_36116234","title":"Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36116234","citation_count":16,"is_preprint":false},{"pmid":"25563599","id":"PMC_25563599","title":"Histone methyltransferase SMYD3 regulates the expression of transcriptional factors during bovine oocyte maturation and early embryonic development.","date":"2015","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/25563599","citation_count":16,"is_preprint":false},{"pmid":"39159723","id":"PMC_39159723","title":"Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/39159723","citation_count":15,"is_preprint":false},{"pmid":"37534166","id":"PMC_37534166","title":"SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37534166","citation_count":15,"is_preprint":false},{"pmid":"30263847","id":"PMC_30263847","title":"SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.","date":"2018","source":"Food science and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30263847","citation_count":15,"is_preprint":false},{"pmid":"34560329","id":"PMC_34560329","title":"Elevated placental histone H3K4 methylation via upregulated histone methyltransferases SETD1A and SMYD3 in preeclampsia and its possible involvement in hypoxia-induced pathophysiological process.","date":"2021","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/34560329","citation_count":15,"is_preprint":false},{"pmid":"29969917","id":"PMC_29969917","title":"SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer.","date":"2018","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29969917","citation_count":15,"is_preprint":false},{"pmid":"37976356","id":"PMC_37976356","title":"The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37976356","citation_count":14,"is_preprint":false},{"pmid":"37192621","id":"PMC_37192621","title":"Mechanical pressure-induced dedifferentiation of myofibroblasts inhibits scarring via SMYD3/ITGBL1 signaling.","date":"2023","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/37192621","citation_count":14,"is_preprint":false},{"pmid":"38091832","id":"PMC_38091832","title":"SMYD3 activates the TCA cycle to promote M1-M2 conversion in macrophages.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38091832","citation_count":14,"is_preprint":false},{"pmid":"33827259","id":"PMC_33827259","title":"H3K4 Methyltransferase Smyd3 Mediates Vascular Smooth Muscle Cell Proliferation, Migration, and Neointima Formation.","date":"2021","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33827259","citation_count":14,"is_preprint":false},{"pmid":"36057625","id":"PMC_36057625","title":"SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36057625","citation_count":13,"is_preprint":false},{"pmid":"35495117","id":"PMC_35495117","title":"Identifying novel SMYD3 interactors on the trail of cancer hallmarks.","date":"2022","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/35495117","citation_count":13,"is_preprint":false},{"pmid":"34510321","id":"PMC_34510321","title":"Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34510321","citation_count":13,"is_preprint":false},{"pmid":"31218443","id":"PMC_31218443","title":"STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo.","date":"2019","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/31218443","citation_count":13,"is_preprint":false},{"pmid":"28019723","id":"PMC_28019723","title":"Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.","date":"2016","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/28019723","citation_count":12,"is_preprint":false},{"pmid":"36127410","id":"PMC_36127410","title":"SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation.","date":"2022","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36127410","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49336,"output_tokens":8366,"usd":0.136749,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18008,"output_tokens":4253,"usd":0.098183,"stage2_stop_reason":"end_turn"},"total_usd":0.234932,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"SMYD3 SET domain possesses histone H3-lysine 4 (H3K4)-specific methyltransferase activity, which is enhanced in the presence of heat-shock protein HSP90A. SMYD3 forms a complex with RNA polymerase II through an interaction with the RNA helicase HELZ and binds to the promoter motif 5'-CCCTCC-3' to transactivate downstream oncogenes and cell-cycle genes.\",\n      \"method\": \"In vitro methyltransferase assay, Co-immunoprecipitation, promoter binding assay, siRNA knockdown with proliferation readout\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro enzymatic assay plus Co-IP plus functional siRNA knockdown, founding paper replicated by multiple subsequent labs\",\n      \"pmids\": [\"15235609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SMYD3 methylates vascular endothelial growth factor receptor 1 (VEGFR1) at lysine 831, located in the kinase domain; this methylation enhances VEGFR1 kinase activity in cells.\",\n      \"method\": \"In vitro methyltransferase assay, mass spectrometry identification of methylated residue, cell-based kinase activity assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro assay plus site identification plus cellular kinase readout, single lab\",\n      \"pmids\": [\"18006819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"N-terminal cleavage of SMYD3 (removing 34 amino acids) increases its histone methyltransferase activity. The N-terminal region mediates association with HSP90alpha, and mutations at conserved glycines 15 and 17 also increase HMTase activity, indicating the N-terminus negatively regulates enzymatic activity.\",\n      \"method\": \"Protein truncation/mutagenesis, in vitro HMTase assay, Co-immunoprecipitation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with in vitro enzymatic assay and Co-IP, single lab\",\n      \"pmids\": [\"17998933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of full-length human SMYD3 in complex with S-adenosyl-L-homocysteine at 2.8 Å resolution reveals that the C-terminal domain contains a tetratricopeptide repeat (TPR) domain that together with the SET and post-SET domains forms a deep, narrow substrate-binding pocket. The hydroxyl group of Tyr239 is critical for enzymatic activity. DNA binding stimulates SMYD3 HMTase activity, potentially mediated via the MYND domain.\",\n      \"method\": \"X-ray crystallography, mutagenesis (Tyr239), biochemical HMTase assay, DNA-binding assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus active-site mutagenesis plus biochemical assays in one study\",\n      \"pmids\": [\"21266482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SMYD3 catalyzes methylation of histone H4 at lysine 5 (H4K5me); this mark is detected in diverse cell types and is attenuated upon SMYD3 depletion. SMYD3-driven cancer cell phenotypes require its enzymatic activity.\",\n      \"method\": \"Mass spectrometry, immunoblot with H4K5me-specific antibody, siRNA knockdown, cancer cell phenotype assays\",\n      \"journal\": \"Epigenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS identification plus antibody validation plus functional knockdown, single lab\",\n      \"pmids\": [\"22419068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SMYD3 methylates MAP3K2 (MEKK2) at lysine 260, potentiating Ras/Raf/MEK/ERK signaling. The PP2A phosphatase complex binds MAP3K2 and this interaction is blocked by SMYD3-mediated methylation, releasing MAP3K2 from negative regulation. Abrogating SMYD3 catalytic activity inhibits Ras-driven pancreatic and lung adenocarcinoma development in mouse models.\",\n      \"method\": \"Protein array substrate identification, in vitro methyltransferase assay, Co-IP, mouse cancer models (Kras-driven), MEK inhibitor synergy assay, site-directed mutagenesis (K260)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro reconstitution, mutagenesis, Co-IP of PP2A displacement, in vivo mouse models, replicated by subsequent structural studies\",\n      \"pmids\": [\"24847881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The C-terminal TPR-like domain of SMYD3 mediates physical interaction with HSP90; this interaction is required for basal HMTase activity and for HSP90-enhanced enzyme activity. Loss of SMYD3-HSP90 interaction causes SMYD3 mislocalization within the nucleus and loss of chromatin association, reducing SMYD3-mediated cell proliferation.\",\n      \"method\": \"Co-immunoprecipitation, domain-deletion mutagenesis, chromatin fractionation, HMTase assay, cell proliferation assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, mutagenesis, fractionation, single lab\",\n      \"pmids\": [\"25738358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SMYD3 functions as a coactivator of estrogen receptor alpha (ERα); it directly interacts with the ligand-binding domain of ERα and is recruited to ER target gene promoters upon estrogen stimulation, where it catalyzes H3K4 di- and trimethylation. SMYD3 knockdown abolishes ER-regulated transcription.\",\n      \"method\": \"Co-immunoprecipitation, ChIP assay, siRNA knockdown, luciferase reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of direct interaction, ChIP evidence of recruitment and H3K4me mark, siRNA functional knockdown, single lab\",\n      \"pmids\": [\"19509295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of SMYD3 co-crystallized with VEGFR1 and MAP3K2 peptides reveal that a phenylalanine at the -2 position of MAP3K2 fits into a shallow hydrophobic pocket on SMYD3, explaining MAP3K2's preference as a substrate over VEGFR1. SMYD3 follows a partially processive mechanism. The inhibitor GSK2807 (Ki=14 nM) bridges the SAM-binding and substrate lysine tunnel pockets.\",\n      \"method\": \"X-ray co-crystal structures, kinetic characterization, inhibitor design and structural validation\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple co-crystal structures plus kinetic mechanistic characterization in one study\",\n      \"pmids\": [\"27066749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Co-crystal structures of SMYD3 with VEGFR1 and MAP3K2 peptides provide structural basis for substrate preference: the phenylalanine at -2 of MAP3K2 confers robust catalytic activity whereas VEGFR1 lysine location in a folded kinase domain requires unfavorable conformational rearrangement, explaining weak activity toward VEGFR1.\",\n      \"method\": \"X-ray crystallography, in vitro biochemical methylation assays with peptide substrates\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures plus quantitative biochemical assays, independently consistent with Van Aller 2016\",\n      \"pmids\": [\"26929412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SMYD3 methylates histone H2A.Z.1 at lysine 101 (H2A.Z.1K101me2), increasing its stability by preventing binding to the removal chaperone ANP32E and facilitating interaction with histone H3. This methylation event activates cyclin A1 expression at its promoter and drives G1-S progression.\",\n      \"method\": \"In vitro methyltransferase assay, mass spectrometry, Co-IP, microarray, ChIP assay, mutagenesis, mouse tumor model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro assay plus MS plus ChIP plus mutagenesis rescue, single lab\",\n      \"pmids\": [\"27569210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SMYD3 methylates AKT1 at lysine 14 in the PH domain both in vitro and in vivo; this methylation is required for AKT1 phosphorylation at threonine 308 (activation) and for plasma membrane accumulation of AKT1. SMYD3 knockdown or pharmacological inhibition attenuates T308 phosphorylation.\",\n      \"method\": \"In vitro methyltransferase assay, site-directed mutagenesis (K14 substitution), subcellular fractionation/membrane localization assay, siRNA knockdown, SMYD3 inhibitor treatment, cell growth assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro assay, mutagenesis, localization and phosphorylation readouts, single lab\",\n      \"pmids\": [\"27626683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In mouse liver and colon cancer models, SMYD3 is localized in the nucleus, interacts with H3K4me3-modified histone tails, and is recruited to core promoter regions. SMYD3 binding increases RNA polymerase II density and transcriptional output of a specific set of oncogenes and cell proliferation genes, including Myc and Ctnnb1. Smyd3 knockout mice are resistant to chemically induced liver and colon cancer.\",\n      \"method\": \"ChIP-seq, RNA-seq, conditional Smyd3 knockout mouse model with chemical carcinogenesis, Co-IP with H3K4me3 tails\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq plus RNA-seq plus in vivo knockout mouse model, multiple orthogonal methods\",\n      \"pmids\": [\"26908355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SMYD3 methyltransferase targets myostatin and c-Met gene regulatory regions in skeletal muscle cells and recruits the bromodomain protein BRD4 through protein-protein interaction. BRD4 recruitment by SMYD3 facilitates engagement of the pause-release factor p-TEFb and elongation of Ser2-phosphorylated RNA Pol II, activating myostatin and c-Met transcription. SMYD3 depletion prevents dexamethasone-induced muscle atrophy in mice.\",\n      \"method\": \"ChIP assay, Co-IP (SMYD3-BRD4 interaction), siRNA knockdown, JQ1 BRD4 inhibitor, in vivo mouse dexamethasone atrophy model\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP, ChIP, pharmacological validation with JQ1, in vivo mouse model, multiple methods\",\n      \"pmids\": [\"23752591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SMYD3 interacts with positive coactivator PC4; this interaction is mutually required for SMYD3 and PC4 co-recruitment to target gene promoters and for SMYD3-mediated H3K4me3 and target gene expression. PC4 depletion abolishes SMYD3-driven H3K4me3 and oncogenic transcription.\",\n      \"method\": \"Co-immunoprecipitation, ChIP assay, siRNA knockdown of PC4, artificial tethering of SMYD3 mutant\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus ChIP plus genetic epistasis by siRNA, single lab\",\n      \"pmids\": [\"26350217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMYD3 directly interacts with SMAD3 (via Co-IP) and is indispensable for SMAD3 association to chromatin at EMT gene regulatory regions during TGFβ signaling. SMYD3 is not required for SMAD2/3 phosphorylation or nuclear translocation but is required for the final chromatin recruitment step. Pharmacological SMYD3 blockade reduces TGFβ-induced mesenchymal gene transcription and invasion in vivo (zebrafish xenograft).\",\n      \"method\": \"Co-immunoprecipitation, ChIP assay, siRNA/pharmacological inhibitor (BCI121), zebrafish xenograft invasion assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, in vivo xenograft, single lab\",\n      \"pmids\": [\"30544196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMYD3 trimethylates HER2 at lysine 175; this methylation enhances HER2 homodimerization, and the K175A substitution reduces homodimer formation and autophosphorylation. SMYD3 knockdown attenuates HER2 autophosphorylation in breast cancer cells.\",\n      \"method\": \"In vitro methyltransferase assay, site-directed mutagenesis (K175A), Co-IP homodimerization assay, siRNA knockdown, phosphorylation immunoblot\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro assay, mutagenesis, Co-IP, cellular phosphorylation assay, single lab\",\n      \"pmids\": [\"28639750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMYD3 methylates RNF113A, and this methylation impairs RNF113A's interaction with the phosphatase PP4, thereby controlling RNF113A phosphorylation levels; the methylation-phosphorylation cross-talk maintains RNF113A E3 ligase activity required for alkylation damage response. SMYD3 inhibition restores SCLC vulnerability to alkylating chemotherapy.\",\n      \"method\": \"In vitro methyltransferase assay, Co-IP (RNF113A-PP4 interaction assay), pharmacological SMYD3 inhibition, chemosensitivity assay, in vivo SCLC model\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro enzymatic assay, Co-IP mechanistic readout, in vivo model, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"35819319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMYD3 phosphorylation by ATM kinase enables formation of a multiprotein complex including ATM, SMYD3, CHK2, and BRCA2, which is required for RAD51 loading at DNA double-strand break sites and completion of homologous recombination. SMYD3 pharmacological inhibition sensitizes HR-proficient cancer cells to PARP inhibitors.\",\n      \"method\": \"Co-IP of ATM-SMYD3-CHK2-BRCA2 complex, RAD51 foci assay, SMYD3 inhibitor + PARP inhibitor synthetic lethality assay, domain mapping using SMYD3 mutant variant\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of multi-protein complex, functional RAD51 loading assay, pharmacological synthetic lethality, single lab\",\n      \"pmids\": [\"33205017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SMYD3 directly interacts with HTLV-1 Tax protein via the C-terminal 180 amino acids of SMYD3; SMYD3 dominates the subcellular localization of Tax, promoting cytoplasmic retention of Tax and enhancing Tax-mediated NF-κB activation. SMYD3 knockdown attenuates NF-κB activation by cytoplasmic Tax.\",\n      \"method\": \"Co-immunoprecipitation, in vitro pull-down, co-localization microscopy, domain-deletion mutagenesis, NF-κB reporter assay, shRNA knockdown\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus in vitro pull-down plus functional reporter assay, single lab\",\n      \"pmids\": [\"21054678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SMYD3 interacts with HCV NS5A via SMYD3's MYND domain and NS5A domain III (mapped by mutagenesis). SMYD3 overexpression decreases intracellular and extracellular HCV virus titers without affecting viral RNA replication, indicating SMYD3 negatively affects particle production in an NS5A-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, co-localization, mutagenesis of MYND domain and NS5A domain III, virus titer assay, RNA replication assay\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping by mutagenesis plus functional titer readout, single lab\",\n      \"pmids\": [\"25092459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMYD3 is recruited by Ebola virus nucleoprotein (NP) to viral inclusion bodies; SMYD3 depletion suppresses EBOV mRNA production and SMYD3 promotes NP-VP30 interaction in a dose-dependent manner, supporting viral transcription.\",\n      \"method\": \"Co-immunoprecipitation (SMYD3-NP), mass spectrometry, minigenome system, siRNA knockdown, co-localization, NP-VP30 interaction assay\",\n      \"journal\": \"Emerging microbes & infections\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus MS identification plus functional minigenome assay, single lab\",\n      \"pmids\": [\"31516086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SMYD3 occupies its binding motifs on the hTERT promoter and is required for H3K4 trimethylation at that locus. SMYD3 knockdown abolishes H3K4me3 at the hTERT promoter, attenuates c-MYC and Sp1 occupancy, reduces histone H3 acetylation, and decreases hTERT mRNA and telomerase activity.\",\n      \"method\": \"ChIP assay, siRNA knockdown, quantitative RT-PCR, telomerase activity assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with histone marks, siRNA functional knockdown, multiple readouts, single lab\",\n      \"pmids\": [\"17363582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMYD3 directly binds the promoter region of Cdkn1a (p21), increases H3K4me3 at that locus, and elevates p21 expression, driving endothelial cell senescence-associated phenotypes. Smyd3 knockout mice are protected from Ang II-induced vascular senescence.\",\n      \"method\": \"ChIP assay, Smyd3 knockout mice, Ang II vascular senescence model, immunoblot, siRNA knockdown\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP direct promoter binding plus in vivo knockout model, single lab\",\n      \"pmids\": [\"32779886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMYD3 binds the promoter of PARP16 and increases H3K4me3 at that locus to activate PARP16 transcription. SMYD3-driven PARP16 upregulation activates ER stress/UPR and promotes smooth muscle cell proliferation and neointimal hyperplasia. Knockdown of either SMYD3 or PARP16 impedes ER stress and SMC proliferation.\",\n      \"method\": \"ChIP-seq, ChIP assay, siRNA knockdown, overexpression, in vivo neointimal hyperplasia model\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus ChIP plus in vivo model, single lab\",\n      \"pmids\": [\"34094832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMYD3 methyltransferase is elevated in Alzheimer's disease PFC and P301S Tau mouse PFC; SMYD3-mediated H3K4me3 upregulates Fbxo2 (E3 ubiquitin ligase), which increases ubiquitination and degradation of NMDAR subunit NR1. SMYD3 inhibition rescues synaptic NMDAR function and cognitive deficits in P301S Tau mice.\",\n      \"method\": \"SMYD3 inhibitor (BCI-121) treatment, electrophysiology, behavioral assays, ChIP assay, Fbxo2 knockdown, ubiquitination assay in mouse PFC\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP mechanistic link plus ubiquitination assay plus in vivo pharmacological rescue plus genetic epistasis (Fbxo2 knockdown), multiple orthogonal methods\",\n      \"pmids\": [\"36609445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMYD3 methylates EZH2 at K421; this methylation accelerates EZH2 ubiquitin-proteasome degradation. Cells harboring non-methylated EZH2 (K421 mutant) show enhanced gastric cancer metastasis, indicating SMYD3-EZH2 methylation restricts rather than promotes metastasis via EZH2 stability.\",\n      \"method\": \"In vitro methyltransferase assay, site-directed mutagenesis (K421), ubiquitination assay, soft agar colony formation, in vivo metastasis model\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro assay plus mutagenesis plus functional cancer assays, single lab\",\n      \"pmids\": [\"36127410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMYD3 depletion in HPV-negative HNSCC induces upregulation of type I interferon response and antigen presentation genes. Mechanistically, SMYD3 binds and activates UHRF1 transcription; UHRF1 reads H3K9me3 at immune gene promoters, recruits DNMT1, and silences their expression. SMYD3 also deposits H4K20me3 intragentically to maintain repression of immune-related genes. In vivo, Smyd3 depletion increases CD8+ T cell infiltration and sensitivity to anti-PD-1 therapy.\",\n      \"method\": \"ChIP-seq, RNA-seq, siRNA/shRNA knockdown, in vivo syngeneic mouse model with anti-PD-1 treatment, UHRF1 epistasis experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq mechanistic pathway plus RNA-seq plus genetic epistasis (UHRF1) plus in vivo immune model, multiple orthogonal methods\",\n      \"pmids\": [\"37463106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMYD3-dependent MAP3K2 methylation promotes EMT-associated behaviors and vimentin upregulation in prostate cancer cells. A positive feedback loop exists whereby SMYD3-MAP3K2-MAPK signaling continually promotes high SMYD3 levels. Both in vitro and xenograft models show SMYD3 catalytic activity is required for these tumor-associated phenotypes.\",\n      \"method\": \"In vitro methyltransferase assay, mutagenesis, siRNA knockdown, mouse xenograft model, EMT marker immunoblot\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro assay plus mutagenesis plus in vivo xenograft, single lab\",\n      \"pmids\": [\"37976356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMYD3 nucleo-cytoplasmic localization is regulated by cell geometry (shape and aspect ratio) via cytoskeletal acto-myosin signaling; elongated shapes reduce nuclear SMYD3 import. Nuclear vs. cytoplasmic distribution of SMYD3 correlates with compartment-specific lysine trimethylation (Kme3) levels, consistent with SMYD3 having both nuclear and cytoplasmic substrates.\",\n      \"method\": \"Live imaging, pharmacological acto-myosin disruption, immunofluorescence with compartment-specific methylation readout\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization imaging with cytoskeletal perturbation and methylation readout, single lab\",\n      \"pmids\": [\"33244033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMYD3 directly interacts with ANKHD1 (identified by mass spectrometry of H3K4me3 pulldown from SMYD3-overexpressing cells). ANKHD1 is required for SMYD3-mediated activation of SLUG gene transcription through H3K4me3 enrichment at the SLUG promoter; ANKHD1 knockdown attenuates the pro-migratory and pro-invasive effects of SMYD3.\",\n      \"method\": \"Mass spectrometry, Co-IP, ChIP (H3K4me3 at SLUG promoter), EMSA, siRNA epistasis (ANKHD1), migration/invasion assay\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS identification, Co-IP, ChIP, genetic epistasis by siRNA, single lab\",\n      \"pmids\": [\"30646949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMYD3 interacts with p53 directly via the post-SET domain; this interaction promotes p53 ubiquitination and proteasomal degradation independent of MDM2. SMYD3 interacts with the ubiquitin-conjugating enzyme UBE2R2, forming a SMYD3-UBE2R2-p53 complex that ubiquitinates p53 at lysines 381, 382, and 386. SMYD3 promotes p53 translocation from nucleus to cytoplasm.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, ubiquitination assay, domain-deletion (post-SET) mapping, site-directed mutagenesis of p53 lysines, subcellular fractionation\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus MS plus mutagenesis plus functional ubiquitination assay, single lab\",\n      \"pmids\": [\"31002112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Smyd3 knockdown in zebrafish embryos using morpholino antisense oligonucleotides causes pericardial edema, trunk structure defects, and abnormal expression of heart-chamber markers (cmlc2, amhc, vmhc) and myogenic regulatory factors (myod, myog), establishing a role for Smyd3 in cardiac and skeletal muscle development.\",\n      \"method\": \"Morpholino knockdown in zebrafish, whole-mount in situ hybridization for developmental markers\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino loss-of-function with specific developmental marker readout, single lab in zebrafish\",\n      \"pmids\": [\"21887258\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMYD3 is a SET domain-containing lysine methyltransferase that operates in both the nucleus and cytoplasm: in the nucleus it methylates H3K4 (mono-, di-, trimethylation), H4K5, H4K20, and H2A.Z.1-K101 to activate or repress specific gene programs (including oncogenes, cell-cycle regulators, and immune response genes), interacting with RNA Pol II, BRD4, PC4, SMAD3, and ANKHD1; in the cytoplasm it methylates non-histone substrates including MAP3K2-K260 (releasing it from PP2A inhibition to potentiate Ras/ERK signaling), VEGFR1-K831 (enhancing kinase activity), AKT1-K14 (promoting membrane localization and T308 phosphorylation), HER2-K175 (promoting homodimerization and autophosphorylation), RNF113A (modulating PP4 interaction and alkylation damage response), and EZH2-K421 (promoting its degradation); its enzymatic activity is stimulated by HSP90 binding to its C-terminal TPR-like domain and by N-terminal cleavage, and its nucleo-cytoplasmic distribution is regulated by cytoskeletal/mechanical cues.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMYD3 is a SET-domain lysine methyltransferase that controls oncogenic and stress-response gene programs by acting on both chromatin and cytoplasmic signaling substrates [#0, #5]. In the nucleus, its SET domain methylates histone H3K4 (including di- and trimethylation), H4K5, and histone variant H2A.Z.1 at K101, the latter stabilizing the nucleosome against the ANP32E removal chaperone to activate cyclin A1 and drive G1-S progression [#0, #4, #10]. SMYD3 is recruited to specific promoters through interaction with RNA polymerase II, the coactivator PC4, BRD4 (which engages p-TEFb to release paused Pol II), the estrogen receptor, SMAD3 during TGFβ-driven EMT, and ANKHD1, thereby transactivating oncogenes, cell-cycle genes, and EMT regulators including Myc, Ctnnb1, hTERT, and SLUG [#7, #12, #13, #14, #15, #22, #30]. Beyond gene activation it also enforces gene silencing, activating UHRF1 transcription and depositing intragenic H4K20me3 to repress type I interferon and antigen-presentation genes, restraining antitumor immunity [#27]. In the cytoplasm SMYD3 methylates non-histone substrates to amplify kinase signaling: MAP3K2-K260 methylation blocks PP2A binding to potentiate Ras/Raf/MEK/ERK signaling and Ras-driven tumorigenesis, AKT1-K14 promotes T308 phosphorylation and membrane localization, and HER2-K175 trimethylation promotes homodimerization and autophosphorylation [#5, #11, #16]. SMYD3 additionally couples to the DNA damage and chemoresistance machinery, methylating RNF113A to sustain its E3 ligase activity in the alkylation response and forming an ATM–CHK2–BRCA2 complex required for RAD51 loading in homologous recombination [#17, #18]. Structurally, a C-terminal TPR domain together with the SET and post-SET domains forms a deep substrate-binding pocket; HSP90 binding to this TPR domain and N-terminal cleavage stimulate catalytic activity, while DNA binding further enhances HMTase activity [#3, #2, #6]. Genetic ablation establishes a causal in vivo requirement for SMYD3 across chemically induced liver/colon cancer, vascular senescence and neointimal hyperplasia, muscle atrophy, and Tau-driven cognitive decline [#12, #13, #23, #24, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established SMYD3 as a sequence-specific transcriptional activator with intrinsic H3K4 methyltransferase activity, defining its founding role in oncogene expression.\",\n      \"evidence\": \"In vitro HMTase assay, Co-IP with Pol II via HELZ, promoter motif binding, siRNA proliferation readout\",\n      \"pmids\": [\"15235609\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve full substrate spectrum beyond H3K4\", \"Mechanism of HSP90 stimulation not yet structurally defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed SMYD3 acts beyond chromatin by methylating a receptor tyrosine kinase, and mapped intrinsic negative regulation by its N-terminus.\",\n      \"evidence\": \"In vitro methylation with MS site mapping (VEGFR1-K831), N-terminal truncation/mutagenesis with HMTase assay and HSP90 Co-IP\",\n      \"pmids\": [\"18006819\", \"17998933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"VEGFR1 was later shown to be a weak substrate structurally\", \"Physiological trigger for N-terminal cleavage unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided the first full-length structure, revealing the TPR-SET-postSET substrate pocket and that DNA binding stimulates catalysis.\",\n      \"evidence\": \"X-ray crystallography with SAH, Tyr239 active-site mutagenesis, DNA-binding HMTase assay\",\n      \"pmids\": [\"21266482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not capture peptide substrates in the pocket\", \"MYND-mediated DNA binding mechanism inferred not proven\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the central oncogenic non-histone mechanism: MAP3K2-K260 methylation displaces PP2A to potentiate Ras/ERK signaling and drive tumorigenesis in vivo.\",\n      \"evidence\": \"Protein-array substrate ID, in vitro methylation, Co-IP of PP2A displacement, Kras-driven mouse cancer models, MEK-inhibitor synergy\",\n      \"pmids\": [\"24847881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not quantify relative flux through histone versus MAP3K2 axes\", \"Reader/effector of K260me beyond PP2A not detailed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Co-crystal structures explained substrate selectivity (-2 phenylalanine of MAP3K2) over VEGFR1 and validated a tractable active-site inhibitor.\",\n      \"evidence\": \"Co-crystal structures with VEGFR1/MAP3K2 peptides, kinetic analysis, GSK2807 inhibitor characterization\",\n      \"pmids\": [\"27066749\", \"26929412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for histone versus non-histone preference not resolved\", \"Processivity implications for cellular output untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Expanded the nuclear and cytoplasmic substrate repertoire to a histone variant and a survival kinase, linking SMYD3 directly to cell-cycle progression and AKT activation.\",\n      \"evidence\": \"In vitro methylation + MS (H2A.Z.1-K101, AKT1-K14), Co-IP with ANP32E/H3, mutagenesis, membrane fractionation, ChIP, mouse tumor model\",\n      \"pmids\": [\"27569210\", \"27626683\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab substrate identifications without independent replication\", \"Stoichiometry of these marks in vivo unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended kinase-activating methylation to HER2, coupling SMYD3 to receptor dimerization in breast cancer.\",\n      \"evidence\": \"In vitro methylation, K175A mutagenesis, Co-IP homodimerization, siRNA, phospho-immunoblot\",\n      \"pmids\": [\"28639750\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct K175me detection in patient tumors not shown\", \"Mechanism linking methylation to dimer interface undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected SMYD3 to the homologous recombination machinery and to mechanical control of its compartmental localization.\",\n      \"evidence\": \"Co-IP of ATM-SMYD3-CHK2-BRCA2 complex, RAD51 foci, PARPi synthetic lethality; live imaging with acto-myosin perturbation and compartment-specific Kme3\",\n      \"pmids\": [\"33205017\", \"33244033\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SMYD3 methylation activity (vs scaffolding) drives HR is unresolved\", \"Cytoplasmic Kme3 substrates not individually mapped in the geometry study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed SMYD3 methylation-phosphorylation cross-talk on RNF113A governs alkylation-damage response and chemosensitivity.\",\n      \"evidence\": \"In vitro methylation, RNF113A-PP4 Co-IP, pharmacological SMYD3 inhibition, chemosensitivity and in vivo SCLC model\",\n      \"pmids\": [\"35819319\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Methylated residue(s) on RNF113A not specified here\", \"Generality across alkylating agents not fully mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed dual transcriptional logic — silencing immune genes via UHRF1/H4K20me3 and tuning substrate stability via EZH2 methylation — and a neurological role through Fbxo2-NMDAR control.\",\n      \"evidence\": \"ChIP-seq/RNA-seq with UHRF1 epistasis and anti-PD-1 model; EZH2-K421 methylation/ubiquitination/metastasis assays; Tau-mouse ChIP, ubiquitination, electrophysiology and behavior\",\n      \"pmids\": [\"37463106\", \"36127410\", \"36609445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SMYD3 switches between activating and repressive chromatin states is unresolved\", \"EZH2-K421 degradation places SMYD3 as metastasis-restraining, contrasting its oncogenic roles — context determinants unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved what determines the partitioning of SMYD3 between its histone-modifying, transcriptional-scaffolding, and cytoplasmic kinase-methylating functions in a given cell, and which of its many substrates dominate in each disease context.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating localization control with substrate choice\", \"Relative contribution of catalytic vs scaffolding activity per pathway untested\", \"Substrate hierarchy in vivo unquantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 11, 16, 17]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [0, 4, 10, 12]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 8]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12, 13, 27]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [13, 14, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [12, 29]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5, 11, 29]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [6, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 12, 13, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 11, 16, 28]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [17, 18]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [10, 12, 27]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [27]}\n    ],\n    \"complexes\": [\n      \"ATM-SMYD3-CHK2-BRCA2 complex\",\n      \"SMYD3-UBE2R2-p53 complex\",\n      \"RNA Pol II complex (via HELZ)\"\n    ],\n    \"partners\": [\n      \"HSP90\",\n      \"BRD4\",\n      \"PC4\",\n      \"SMAD3\",\n      \"ANKHD1\",\n      \"MAP3K2\",\n      \"EZH2\",\n      \"RNF113A\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}